BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 37137403)

  • 1. Biomaterials for chimeric antigen receptor T cell engineering.
    Niu H; Zhao P; Sun W
    Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomaterials promote
    Qin YT; Li YP; He XW; Wang X; Li WY; Zhang YK
    Front Immunol; 2023; 14():1165576. PubMed ID: 37153571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
    Cardle II; Cheng EL; Jensen MC; Pun SH
    Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment.
    Lin Y; Chen Y; Luo Z; Wu YL
    Nanoscale; 2024 Feb; 16(7):3226-3242. PubMed ID: 38284230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells.
    Li T; Luo R; Su L; Lv F; Mei L; Yu Y
    Small Methods; 2023 Nov; 7(11):e2300880. PubMed ID: 37653606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
    Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
    Zhang C; Zhuang Q; Liu J; Liu X
    ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
    Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
    Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
    Rafiq S; Hackett CS; Brentjens RJ
    Nat Rev Clin Oncol; 2020 Mar; 17(3):147-167. PubMed ID: 31848460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
    Mao R; Hussein MS; He Y
    Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
    Irving M; Lanitis E; Migliorini D; Ivics Z; Guedan S
    Hum Gene Ther; 2021 Oct; 32(19-20):1044-1058. PubMed ID: 34662233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.